
Vericel Corp
VCELHealthcare|Biotechnology|USA
$47.00
-1.32 (-2.73%)
DCF (FCF)
$9.33
Tangible Book
$6.88
Graham Number
$8.06
Earnings Power
$1.32
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
332.2,
388.69,
452.73,
522.04,
665.63
],
"ebit_estimate": [
23.97,
49.64,
84.56,
125.35,
180.96
],
"ebitda_estimate": [
89.37,
116.4,
151.3,
194.57,
null
],
"net_income_estimate": [
24.64,
43.33,
74.61,
103.14,
142.96
],
"per_share_eps_estimate": [
0.47,
0.88,
1.37,
1.76,
2.26
],
"eps_nri_estimate": [
0.47,
0.88,
1.37,
1.76,
2.26
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
0.64,
null,
null,
null,
null
],
"pretax_income_estimate": [
28.75,
54.3,
88.56,
117.07,
180.96
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
74.96,
75.64,
76.3,
78,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null
],
"pettm_estimate": [
99.37,
53.65,
34.23,
26.78,
20.8
],
"long_term_growth_rate_mean": 64.63,
"long_term_revenue_growth_rate_mean": "17.81",
"future_per_share_eps_estimate_growth": 64.63,
"future_eps_nri_estimate_growth": 64.63,
"future_revenue_estimate_growth": 17.81,
"future_ebit_estimate_growth": 98.07,
"future_ebitda_estimate_growth": 28.89,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 66.35,
"future_pretax_income_estimate_growth": 73.71,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 0.84,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
72.69,
79.47,
111.62,
79.51,
87.52,
90.92,
132.53,
93.75
],
"ebit_estimate": [
-2.82,
3.63,
31.23,
-2.93,
4.34,
9.1,
40.35,
1.08
],
"ebitda_estimate": [
13.2,
18.74,
47.89,
13.22,
20.5,
25.28,
56.44,
17.71
],
"net_income_estimate": [
-1.53,
4.31,
28.14,
-1.35,
4.99,
8.87,
34.91,
1.6
],
"per_share_eps_estimate": [
-0.03,
0.08,
0.54,
-0.04,
0.11,
0.16,
0.62,
0.02
],
"eps_nri_estimate": [
-0.03,
0.08,
0.54,
-0.04,
0.11,
0.16,
0.62,
0.04
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
0.05,
0.08,
0.55,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-1.54,
4.89,
32.08,
-1.36,
5.94,
10.77,
42.08,
2.01
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
72.96,
73.77,
79,
72.08,
74.05,
75,
79.1,
73
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
84.99,
67.92,
60.8,
54.84,
51.37,
null,
null,
null
],
"long_term_growth_rate_mean": 64.63,
"long_term_revenue_growth_rate_mean": "17.81",
"future_per_share_eps_estimate_growth": 64.63,
"future_eps_nri_estimate_growth": 64.63,
"future_revenue_estimate_growth": 17.81,
"future_ebit_estimate_growth": 98.07,
"future_ebitda_estimate_growth": 28.89,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 66.35,
"future_pretax_income_estimate_growth": 73.71,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 0.84,
"future_operating_cash_flow_per_share_estimate_growth": null
}